Hympavzi

Indicated For

Hemophilia A, Hemophilia B

About This Medication

# Pfizer Patient Assistance Program Guide: Getting Hympavzi at Low Cost ## What is Hympavzi? Hympavzi (marstacimab-hncq) is a prescription medication made by Pfizer used to treat hemophilia A and hemophilia B. It's an important therapy that helps prevent bleeding episodes, but it can be expensive. If you're struggling to afford Hympavzi, Pfizer's Patient Assistance Program (PAP) may help you get this medication at little or no cost. ## Who Can Apply? ### Insurance Status You are eligible if you have: - **No insurance (uninsured)** - **Government insurance** like Medicare, Medicaid, or TRICARE **Important:** If you have commercial insurance (private insurance through an employer or individual plan), you are **not eligible** for this program. You may want to ask your insurance company about coverage or talk to your doctor about other options. ### Income Requirements Your household income must fall below certain limits. Income thresholds vary based on your family size and location. Here's a general example: | Family Size | Approximate Annual Income Limit | |---|---| | 1 person | $23,000–$35,000 | | 2 people | $31,000–$47,000 | | 3 people | $39,000–$59,000 | | 4 people | $47,000–$71,000 | | 5+ people | Add ~$8,000–$12,000 per person | *Note: These are estimates. Exact limits vary by state and change annually. Pfizer will confirm your eligibility during the application process.* ## What You Need to Apply Before you start, gather these documents: 1. **Proof of Income** - Recent tax return (last 2 years) - Pay stubs from the last 2–3 months - Benefit statements (if you receive unemployment, Social Security, or disability) - For self-employed individuals: business tax returns 2. **Proof of Insurance Status** - Insurance card (front and back) if you have Medicare or Medicaid - Letter from your insurance company confirming your status - For uninsured: a simple statement that you have no health insurance 3. **Valid Prescription** - A signed prescription from your doctor for Hympavzi - Your doctor's contact information ## How to Apply (4 Steps) **Step 1: Contact Pfizer** Call the Pfizer Patient Assistance Program at **(844) 989-7284**. A specialist will answer your questions and confirm you meet basic eligibility requirements. Alternatively, visit **https://www.pfizerrxpathways.com** to apply online. **Step 2: Submit Your Documents** You can apply in multiple ways: - **Online:** Upload documents through the Pfizer RxPathways website - **Phone:** Call (844) 989-7284 to mail or fax documents - **Mail:** Send documents directly (the phone representative will provide the address) **Step 3: Wait for Approval** Pfizer will review your application. Most applicants hear back within **2–3 weeks**, though some applications may take longer if additional information is needed. **Step 4: Start Getting Your Medication** Once approved, Hympavzi will be shipped directly to your home or to your pharmacy at no cost (or a small copay). You don't need to pay anything upfront. ## Annual Reauthorization Your assistance is approved for **one year**. Before your year ends, you'll need to reapply with updated income and insurance information. Pfizer will send you a reminder when it's time to reauthorize. ## Savings Card Option If you don't qualify for the full assistance program, you may be eligible for Pfizer's **savings card**, which reduces your out-of-pocket costs. Ask about this when you call. ## Important Reminders - **No biosimilars available:** There are no generic or biosimilar versions of Hympavzi yet. - **Keep your doctor involved:** Pfizer works directly with your doctor to manage your prescription. - **Be honest on your application:** Providing false income or insurance information can result in program termination and legal consequences. ## Need Help? If you have questions or your application is denied, call **(844) 989-7284**. Pfizer specialists can explain next steps, help with appeals, or discuss alternative payment plans.

Program information last verified: March 25, 2026